Full-Time

Machine Learning Engineer III

Confirmed live in the last 24 hours

PathAI

PathAI

201-500 employees

AI-powered pathology platform for diagnostics

No salary listed

Mid, Senior

Boston, MA, USA + 2 more

More locations: Remote in USA | New York, NY, USA

New York is preferred; remote work is also an option.

Category
Applied Machine Learning
Deep Learning
Computer Vision
AI & Machine Learning
Required Skills
Python
Tensorflow
Pytorch
Machine Learning
Pandas
NumPy
Computer Vision
Requirements
  • Master’s degree plus 3-4 years of professional experience or Ph. D. in Computer Science, Computational Biology or related field, preferably with a focus on artificial intelligence and machine learning
  • 3-4 years of experience in developing and deploying state-of-the art machine learning models in products
  • Excellent proficiency in Deep Learning frameworks (Pytorch/Tensorflow), Python (including Scipy, Numpy, Pandas) and software engineering skills
  • Strong analytical and quantitative skills
  • Strong track record with the overall machine learning and computer vision model development process including data pipelines, model training, evaluation and deployment
  • Strong communication skills
  • Intellectual curiosity and the ability to learn quickly in a complex space
Responsibilities
  • Independently lead the planning and execution of machine learning model development for research and product development projects with ML best practices
  • Contributes towards internal product and translational research experiment design, ideation, analysis, documentation and experimental plans
  • Understands product requirements in their biological and clinical context and proposes changes to model design, product requirements, or analysis plan to ensure market fit
  • Demonstrates mastery of established and state-of-the-art ML methods and upholds ML Team’s best practices for ML research and product development
  • Engaged within team governance of standards via supporting initiatives (e.g. Guild of TLs, ML Stewards, WiML, Journal Club, Maintaining and creation of documentation)
  • Identify technical gaps, propose and initiate new projects by articulating rationale and experimental plans that translate technical improvements into business impact
  • Actively participate in and propose improvements to team processes and supporting initiatives, including but not limited to: project processes, technical design reviews, knowledge sharing, hiring and onboarding
  • Actively support scientific strategy with abstract submissions to conferences, manuscript preparation, and creation of marketing and other materials for external audiences
Desired Qualifications
  • Publications or research in fields related to artificial intelligence and biomedical science is strongly preferred

PathAI focuses on improving patient outcomes by using an AI-powered pathology platform. This platform enhances the accuracy of diagnoses and the effectiveness of treatments for diseases like cancer through advanced machine learning techniques. PathAI provides diagnostic tools and services to healthcare providers, research institutions, and pharmaceutical companies, generating revenue through partnerships, licensing, and service fees. What sets PathAI apart from its competitors is its commitment to solving complex healthcare problems with a diverse team and a focus on making a significant impact in the medical field. The company's goal is to ensure better patient outcomes by leveraging technology in pathology.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$358.7M

Headquarters

Boston, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI's collaboration with Precision for Medicine enhances clinical trial services with AI tools.
  • The launch of PathAssist Derm addresses the high prevalence of skin cancer with AI solutions.
  • Partnership with Discovery Life Sciences automates workflows, enhancing tissue-level insights.

What critics are saying

  • Increased competition from companies like Deep Bio could dilute PathAI's market share.
  • Rapid AI advancements may outpace PathAI's offerings, affecting competitiveness.
  • PathAssist Derm may face adoption challenges if it doesn't integrate well with existing systems.

What makes PathAI unique

  • PathAI offers end-to-end automation for scalable, cost-effective pathology solutions.
  • The company focuses on AI-powered tools to enhance diagnostic accuracy and treatment efficacy.
  • PathAI's platform integrates advanced machine learning for improved patient outcomes in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive medical, dental, and vision insurance

Retirement plan options

Paid parental leave

Health & wellness benefits

Flexible work options

Generous paid time off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
PR Newswire
May 5th, 2025
Precision For Medicine Welcomes Matt Grow As Chief Commercial Officer

-- Brings over two decades' experience leading business development and crafting go-to-market solutions for clinical research organizations --BETHESDA, Md., April 29, 2025 /PRNewswire/ -- Precision for Medicine, a global leader in biomarker-driven clinical research and development, today announced the appointment of Matt Grow as Chief Commercial Officer. In this role, Mr. Grow will focus on implementing a go-to-market strategy that positions Precision for Medicine as the premier partner to help life science companies accelerate clinical research and development

PR Newswire
Apr 25th, 2025
Precision For Medicine And Pathai Announce Strategic Collaboration To Advance Ai-Powered Clinical Trial Services And Biospecimen Products

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discoveryBOSTON and FREDERICK, Md., April 25, 2025 /PRNewswire/ -- Precision for Medicine, a leading provider of next generation drug development research and services, and PathAI, a global leader in digital pathology, today announced a strategic collaboration to partner on developing novel AI-based technologies and to integrate PathAI's advanced digital pathology and analysis capabilities across Precision for Medicine's clinical trial and biospecimen operations. This collaboration includes use of several PathAI technologies and establishes an agreement to offer novel tools and analytical services that address emerging needs in biomarker discovery, spatial biology, and tissue-based clinical research. Through this collaboration PathAI's tools and services will help augment Precision for Medicine's proprietary pipeline providing biopharma clients with access to imaging workflows offered through Precision for Medicine's integrated laboratory and clinical trial services

Hit Consultant
Apr 25th, 2025
Precision For Medicine & Pathai Launch Strategic Ai Digital Pathology Partnership

Precision for Medicine PathAI Launch Strategic AI Digital Pathology Partnership. by Fred Pennic 04/25/2025 Leave a Comment. What You Should Know: – Precision for Medicine, a provider of next-generation drug development research and services, and PathAI, a global leader in digital pathology, announced a strategic collaboration today.– The partnership aims to jointly develop novel AI-based technologies and integrate PathAI’s advanced digital pathology and analysis capabilities across Precision for Medicine’s comprehensive clinical trial and biospecimen operations.AI-Powered Clinical Trial Services and Biospecimen ProductsAs part of the agreement, Precision for Medicine will deploy selected technologies from PathAI, including its AISight® digital pathology image management system and other AI-powered algorithms. These tools will enhance Precision for Medicine’s biospecimen analysis workflows by incorporating validated, algorithm-based quality control steps, thereby improving data consistency and reliability. PathAI’s capabilities will augment Precision for Medicine’s proprietary service pipeline, offering biopharma clients integrated imaging workflows accessible through Precision’s laboratory and clinical trial services.The collaboration will also leverage PathAI’s leading AI and machine learning models to enrich Precision for Medicine’s multi-modal datasets. This advanced technology facilitates the reduction of large, complex biomarker panels into scalable, actionable insights crucial for interpreting complex tissue biology

Hit Consultant
Feb 4th, 2025
Pathai Launches Pathassist Derm, An Ai-Powered Tool For Skin Lesion Analysis

What You Should Know:– PathAI, a provider of AI-powered pathology solutions, today announced the launch of PathAssist Derm, an innovative tool designed to streamline the analysis of skin lesions.– Available now on the AISight® Image Management System (IMS), this research tool automates specimen orientation and identification, enabling pathologists to review samples more efficiently and accurately.PathAssist Derm CapabilitiesPathAssist Derm is the latest addition to PathAI’s suite of AI-powered solutions available on the AISight® IMS. This comprehensive platform provides pathologists with a range of tools to streamline their workflows and improve diagnostic accuracy. PathAssist Derm offers several key capabilities:Automated Specimen Orientation: Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors.Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors. Lesion Identification: Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research.Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research. Detailed Measurements: Provides precise measurements of lesion size and characteristics, facilitating quantitative analysis.“Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone,” said Andrew Beck, Co-Founder & CEO of PathAI. “These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms

Hit Consultant
Jan 23rd, 2025
Pathai Partners To Deploy First Ai-Powered Biospecimen Solutions

What You Should Know:– PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.– This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.Transforming Pathology Workflow: PathAI and Discovery Life Sciences Partner to Advance Precision MedicinePathAI and Discovery Life Sciences have entered a strategic partnership to integrate PathAI’s AISight® Image Management System (IMS), ArtifactDetect, and TumorDetect products into Discovery’s global biospecimens business. This collaboration aims to revolutionize traditional pathology workflows by automating routine tasks, enabling pathologists to dedicate more time to complex analyses, and empowering Discovery’s customers with enhanced tissue-level quantitative insights.Key Highlights of the Partnership:Automation of Pathology Workflows: PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency.PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency. Enhanced Data Quality: Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs.Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs. Custom AI-Driven Solutions: The partnership includes the development of a proprietary AI-driven tissue analysis panel exclusive to Discovery, advancing translational research and biomarker discovery for biopharma partners.Expanding AI-Driven InnovationsThis partnership extends beyond Discovery’s biospecimens business to include potential applications within Discovery’s Specialty Lab Services. These AI-driven solutions are expected to accelerate drug development and precision medicine by providing advanced insights for biopharma research initiatives.Advancing Precision Medicine and DiagnosticsWith increasing investments in immuno-oncology and antibody-drug conjugates, the demand for precise diagnostic tools that optimize patient selection continues to grow. By combining PathAI’s cutting-edge technology with Discovery’s structured, multi-modal datasets, the partnership aims to:Accelerate the development of new assays and diagnostic tools.Enhance the reliability and speed of biomarker discovery.Improve patient outcomes through advanced diagnostic precision.Leadership Perspective“Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in pathology assessments, ultimately benefiting their customers with enhanced data quality and insights,” said Andy Beck, CEO of PathAI